FDA seeks public input on Biosimilar User Fee Act reauthorization for FY 2028-2032

FDA will hold a hybrid public meeting and accept written comments through November 25, 2026, on recommendations to reauthorize the Biosimilar User Fee Act before its current authority expires in September 2027. The Food and Drug Administration (FDA) announced a hybrid public meeting to discuss...